Coronary artery bypass surgery perioperative management of myocardial dysfunction
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery perioperative management of myocardial dysfunction On the Web | |
|
FDA on Coronary artery bypass surgery perioperative management of myocardial dysfunction | |
|
CDC on Coronary artery bypass surgery perioperative management of myocardial dysfunction | |
|
Coronary artery bypass surgery perioperative management of myocardial dysfunction in the news | |
|
Blogs on Coronary artery bypass surgery perioperative management of myocardial dysfunction|- |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Perioperative Myocardial Dysfunction (DO NOT EDIT)[1]
| Class IIa |
| "1. In the absence of severe, symptomatic aorto-iliac occlusive disease or peripheral artery disease, the insertion of an intra-aortic balloon is reasonable to reduce mortality rate in CABG patients who are considered to be at high risk (eg, those who are undergoing reoperation or have LVEF <30% or left main CAD).[2][3][4][5][6][7] (Level of Evidence: B)" |
| "2. Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.[8] (Level of Evidence: B)" |
Guidelines Resources
- 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[1]
References
- ↑ 1.0 1.1 1.2 Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.
- ↑ Christenson JT, Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Ohman EM; et al. (2002). "Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery". Ann Thorac Surg. 74 (4): 1086–90, discussion 1090-1. PMID 12400750.
- ↑ Christenson JT, Simonet F, Badel P, Schmuziger M (1999). "Optimal timing of preoperative intraaortic balloon pump support in high-risk coronary patients". Ann Thorac Surg. 68 (3): 934–9. PMID 10509987.
- ↑ Christenson JT, Licker M, Kalangos A (2003). "The role of intra-aortic counterpulsation in high-risk OPCAB surgery: a prospective randomized study". J Card Surg. 18 (4): 286–94. PMID 12869172.
- ↑ Christenson JT, Schmuziger M, Simonet F (2001). "Effective surgical management of high-risk coronary patients using preoperative intra-aortic balloon counterpulsation therapy". Cardiovasc Surg. 9 (4): 383–90. PMID 11420164.
- ↑ Urban PM, Freedman RJ, Ohman EM, Stone GW, Christenson JT, Cohen M; et al. (2004). "In-hospital mortality associated with the use of intra-aortic balloon counterpulsation". Am J Cardiol. 94 (2): 181–5. doi:10.1016/j.amjcard.2004.03.058. PMID 15246896.
- ↑ Santa-Cruz RA, Cohen MG, Ohman EM (2006). "Aortic counterpulsation: a review of the hemodynamic effects and indications for use". Catheter Cardiovasc Interv. 67 (1): 68–77. doi:10.1002/ccd.20552. PMID 16342217.
- ↑ Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N; et al. (2008). "Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)". Am J Cardiol. 102 (5): 546–51. doi:10.1016/j.amjcard.2008.04.069. PMID 18721510.